At AB-BIOTICS S.A., we are committed to ensuring that probiotic products on the market accurately reflect their strain composition—especially when referencing patented combinations such as AB-Kolicare®, which includes Pediococcus pentosaceus CECT8330 and Bifidobacterium longum subsp. longum CECT7894.
In April 2025, our team conducted a targeted inspection of probiotic oil-drop products commercially available in China that either explicitly claimed or suggested the inclusion of these strains. These products were neither produced by nor authorized by AB-BIOTICS S.A.
Using qPCR and conventional PCR methodologies, we evaluated the microbial content of multiple product batches. The results revealed notable discrepancies:
- Several products did not reach the clinically effective dose of the strains.
- One product failed to contain the target strain at all, despite claims implying its presence.
These findings highlight ongoing challenges in quality control and labeling integrity in the probiotic sector. AB-BIOTICS will continue to perform random audits to protect both intellectual property and public health, and to promote scientific transparency in the industry.
Read the full inspection statement here for detailed results and methodology.